Should You Sell Design Therapeutics Inc (DSGN) in Biotechnology Industry?

A rating of 29 puts Design Therapeutics Inc (DSGN) near the bottom of the Biotechnology industry according to InvestorsObserver. Design Therapeutics Inc's score of 29 means it scores higher than 29% of stocks in the industry. Design Therapeutics Inc also received an overall rating of 34, putting it above 34% of all stocks. Biotechnology is ranked 72 out of the 148 industries.

DSGN has an Overall Score of 34. Find out what this means to you and get the rest of the rankings on DSGN!

See Full DSGN Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 34 means the stock is more attractive than 34 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Design Therapeutics Inc Stock Today?

Design Therapeutics Inc (DSGN) stock is lower by -0.81% while the S&P 500 is higher by 0.02% as of 2:13 PM on Friday, Sep 1. DSGN has fallen -$0.02 from the previous closing price of $2.48 on volume of 823,901 shares. Over the past year the S&P 500 is higher by 13.66% while DSGN has fallen -88.52%. DSGN lost -$1.33 per share the over the last 12 months. Click Here to get the full Stock Report for Design Therapeutics Inc stock.